Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-549 | PI103 | 3 | 72 | 0.001 | 3692.5 | 3977.0 | 1175.8 | -3.0 | 0.917 | 0.928 | 1.758 | BT549 PI103 0 3 72 |
| HCC70 | AZD-6482 | 3 | 72 | 0.001 | 2842.0 | 2991.0 | 517.3 | -3.0 | 0.960 | 0.950 | 2.532 | HCC70 AZD6482 0 3 72 |
| BT-549 | TGX221 | 1 | 72 | 0.001 | 5293.5 | 5515.0 | 1554.9 | -3.0 | 0.956 | 0.960 | 1.826 | BT549 TGX221 0 1 72 |
| BT-20 | Torin2 | 3 | 72 | 0.001 | 2975.8 | 3225.3 | 586.9 | -3.0 | 0.936 | 0.923 | 2.458 | BT20 Torin2 0 3 |
| BT-20 | AS605240 | 1 | 72 | 0.001 | 5834.8 | 6371.0 | 1443.3 | -3.0 | 0.920 | 0.916 | 2.142 | BT20 AS605240 0 1 |
| BT-20 | Everolimus | 2 | 72 | 0.001 | 1803.0 | 3213.5 | 1018.6 | -3.0 | 0.411 | 0.561 | 1.658 | BT20 Everolimus 0 2 |
| BT-20 | Sirolimus | 1 | 72 | 0.001 | 3625.0 | 5856.5 | 1443.3 | -3.0 | 0.577 | 0.619 | 2.021 | BT20 Rapamycin 0 1 |
| BT-20 | WYE-125132 | 3 | 72 | 0.001 | 3058.5 | 3344.0 | 586.9 | -3.0 | 0.930 | 0.915 | 2.510 | BT20 WYE125132 0 3 |
| BT-20 | Everolimus | 1 | 72 | 0.001 | 3773.0 | 5781.0 | 1443.3 | -3.0 | 0.616 | 0.653 | 2.002 | BT20 Everolimus 0 1 |
| BT-20 | TGX221 | 2 | 72 | 0.001 | 2691.8 | 3211.0 | 1018.6 | -3.0 | 0.798 | 0.838 | 1.656 | BT20 TGX221 0 2 |
| BT-20 | Sirolimus | 2 | 72 | 0.001 | 1740.0 | 3606.8 | 1018.6 | -3.0 | 0.341 | 0.482 | 1.824 | BT20 Rapamycin 0 2 |
| BT-20 | ZSTK474 | 3 | 72 | 0.001 | 3277.0 | 3579.5 | 586.9 | -3.0 | 0.933 | 0.915 | 2.609 | BT20 ZSTK474 0 3 |
| BT-20 | Buparlisib | 1 | 72 | 0.001 | 5907.8 | 6321.8 | 1443.3 | -3.0 | 0.937 | 0.935 | 2.131 | BT20 BKM120 0 1 |
| BT-20 | Pictilisib | 2 | 72 | 0.001 | 2270.3 | 3416.0 | 1018.6 | -3.0 | 0.583 | 0.665 | 1.746 | BT20 GDC0941 0 2 |
| BT-549 | Torin2 | 1 | 72 | 0.001 | 4776.3 | 5306.0 | 1554.9 | -3.0 | 0.885 | 0.900 | 1.771 | BT549 Torin2 0 1 72 |
| BT-20 | CAL-101 | 3 | 72 | 0.001 | 3235.5 | 3531.5 | 586.9 | -3.0 | 0.934 | 0.916 | 2.589 | BT20 CAL101 0 3 |
| BT-549 | Trametinib | 1 | 72 | 0.001 | 5342.5 | 5460.3 | 1554.9 | -3.0 | 0.976 | 0.978 | 1.812 | BT549 Trametinib 0 1 72 |
| BT-549 | WYE-125132 | 1 | 72 | 0.001 | 5190.5 | 5366.3 | 1554.9 | -3.0 | 0.963 | 0.967 | 1.787 | BT549 WYE125132 0 1 72 |
| BT-20 | Omipalisib | 2 | 72 | 0.001 | 3128.0 | 3349.0 | 1018.6 | -3.0 | 0.922 | 0.934 | 1.717 | BT20 GSK458 0 2 |
| BT-549 | WYE-125132 | 3 | 72 | 0.001 | 3714.5 | 3719.8 | 1175.8 | -3.0 | 0.998 | 0.999 | 1.662 | BT549 WYE125132 0 3 72 |
| BT-20 | AZD8055 | 1 | 72 | 0.001 | 5501.0 | 5941.5 | 1443.3 | -3.0 | 0.926 | 0.926 | 2.041 | BT20 AZD8055 0 1 |
| BT-20 | GDC-0980 | 2 | 72 | 0.001 | 3333.5 | 3217.8 | 1018.6 | -3.0 | 1.040 | 1.040 | 1.659 | BT20 GDC0980 0 2 |
| BT-20 | TGX221 | 1 | 72 | 0.001 | 5503.5 | 5723.8 | 1443.3 | -3.0 | 0.961 | 0.962 | 1.988 | BT20 TGX221 0 1 |
| HCC70 | GDC-0980 | 3 | 72 | 0.001 | 2859.8 | 2773.8 | 517.3 | -3.0 | 1.030 | 1.030 | 2.423 | HCC70 GDC0980 0 3 72 |
| HCC70 | Pictilisib | 3 | 72 | 0.001 | 2889.0 | 2827.0 | 517.3 | -3.0 | 1.020 | 1.020 | 2.450 | HCC70 GDC0941 0 3 72 |